Serum hypoxia-inducible factor-2: A candidate prognostic biomarker for laryngeal cancer


Creative Commons License

Eskiizmir G., Çalıbaşı Koçal G., Uysal T., Ellidokuz H., Başbınar Y.

CLINICAL OTOLARYNGOLOGY, vol.46, no.6, pp.1172-1183, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 46 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1111/coa.13789
  • Journal Name: CLINICAL OTOLARYNGOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Page Numbers: pp.1172-1183
  • Keywords: biomarker, hypoxia, hypoxia inducible factor, larynx cancer, prognosis, survival, SQUAMOUS-CELL CARCINOMA, TUMOR MICROENVIRONMENT, CA-IX, CLINICAL-RELEVANCE, PREDICTIVE-VALUE, GROWTH-FACTOR, RISK-FACTORS, HEAD, HIF-2-ALPHA, ANEMIA
  • Dokuz Eylül University Affiliated: Yes

Abstract

Objectives To determine the serum hypoxia-inducible factor-1, -2 and -3 (HIF-1, -2 and -3) levels in patients with laryngeal neoplasm, and to investigate their role in differential diagnosis, prediction of tumour characteristic and extension, and prognosis and survival. Study Design Prospective, cohort study at a tertiary referral centre. Settings The study was conducted in a tertiary medical centre. Participants Patients with benign, premalignant and malignant laryngeal neoplasms were included. Sixty-four patients with a laryngeal neoplasm were enrolled. Main Outcome Measures Serum HIF-1, -2 and -3 levels were measured from blood samples that were drawn before treatment, using ELISA. Results A statistically significant difference between benign (HIF-1, -2, -3:4046,1 pg/mL; 2581,5 pg/mL; 1321,0 pg/mL), premalignant (HIF-1, -2, -3:3630,3 pg/mL; 3229,7 pg/mL; 2549,8 pg/mL) and malignant (HIF-1, -2, -3:3576,7 pg/mL; 2595,8 pg/mL; 1106,3 pg/mL) laryngeal neoplasms was not detected when serum HIF-1, -2 and -3 levels were compared. However, high serum HIF-2 level adversely affected survival and locoregional control and had more than 7-fold increase in hazard ratio. Moreover, serum HIF-2 was an independent prognostic factor for 2-year overall, disease-free, distant metastasis-free survival and locoregional control. Conclusion This is the first clinical study in which the diagnostic, predictive and prognostic roles of hypoxia-related biomolecules were examined in laryngeal neoplasms. Hypoxia-inducible factor-2 is a prognostic factor in larynx cancer irrespective of treatment modality.